Published in Am J Pathol on September 01, 1996
STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A (1999) 1.96
miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate (2010) 1.55
Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics (2009) 1.27
Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol (2010) 1.15
Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One (2013) 1.09
Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours. Br J Cancer (2011) 1.05
Mouse models of prostate cancer. Prostate Cancer (2011) 1.04
Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging (2007) 0.99
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol (2002) 0.97
Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA (2000) 0.97
Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol (2001) 0.95
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer (2008) 0.95
Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum Gene Ther (2011) 0.95
Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol (2001) 0.92
Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep (2015) 0.90
The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl (2008) 0.90
Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer (1999) 0.90
Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res (2010) 0.90
Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol (1999) 0.86
Next generation patient-derived prostate cancer xenograft models. Asian J Androl (2014) 0.85
Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer (2012) 0.85
Human prostate cancer heterotransplants: a review on this experimental model. Asian J Androl (2010) 0.83
A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum Gene Ther (2011) 0.83
Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer (2000) 0.81
Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med (2009) 0.80
Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. Biomed Res Int (2016) 0.78
Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol (2017) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Basement membrane complexes with biological activity. Biochemistry (1986) 6.79
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J Natl Cancer Inst (1991) 2.86
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res (1991) 1.87
Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst (1993) 1.80
CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res (1994) 1.77
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 1.63
Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res (1991) 1.61
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). Prostate (1980) 1.08
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate (1993) 0.97
Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol (1991) 0.96
Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem (1994) 0.93
The use of steroid-containing Silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. Prostate (1984) 0.88
Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC-82. Prostate (1986) 0.86
Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice. Prostate (1984) 0.85
The nude mouse--its use as tumor-bearing model of the prostate. Prog Clin Biol Res (1980) 0.83
Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82). J Urol (1984) 0.81
Microscopic haematuria. BMJ (1994) 3.00
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate (1995) 2.07
Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. Hum Pathol (1999) 2.06
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res (2001) 1.86
Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol (1993) 1.82
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst (2000) 1.78
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Future prospects in prostate cancer. Prostate (1999) 1.53
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology (2006) 1.51
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (2003) 1.46
Sperm DNA integrity in cancer patients before and after cytotoxic treatment. Hum Reprod (2010) 1.45
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
Volumetric measurements of bone mineral density of the lumbar spine: comparison of three geometrical approximations using dual-energy X-ray absorptiometry (DXA) Nucl Med Commun (1998) 1.37
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Detection of prostate cancer. BMJ (1995) 1.30
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab (2001) 1.22
Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem (1991) 1.20
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol (1997) 1.16
Detection of factor VIII/coagulant antigen in human liver tissue. Nature (1983) 1.16
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res (1990) 1.14
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med (2000) 1.11
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol (1998) 1.10
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry (1992) 1.08
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol (1996) 1.07
Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen (1996) 1.06
Hormonal manipulation of prostatic cancer. BMJ (1991) 1.06
Use of nude mouse xenograft models in prostate cancer research. Prostate (2000) 1.05
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05
Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun (1989) 1.05
Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05
Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate (1993) 1.05
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet (2000) 1.04
Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) (2002) 1.04
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate (1999) 1.04
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol (1998) 1.04
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review. Urol Res (1989) 1.04
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol (1995) 1.03
An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol (1993) 1.03
Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo. Am J Pathol (1994) 1.02
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int (1995) 1.01
Screening for prostate cancer. Eur J Cancer (2005) 1.01
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene (2000) 0.99
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol (1998) 0.99
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol (1990) 0.98
Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer (2001) 0.98
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int (2004) 0.98